Published 14 days ago • loading... • Updated 14 days ago

Quebec Implements Public Reimbursement of Pluvicto® – A Defining Milestone for Radioligand Therapy in Canada - Life Sciences British Columbia

Novartis Pharmaceuticals Canada Inc. is pleased to announce that, as of July 2, 2025, Pluvicto® is publicly reimbursed in Quebec.

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

lifesciencesbc.ca

Quebec Implements Public Reimbursement of Pluvicto® – A Defining Milestone for Radioligand Therapy in Canada - Life Sciences British Columbia

Novartis Pharmaceuticals Canada Inc. is pleased to announce that, as of July 2, 2025, Pluvicto® is publicly reimbursed in Quebec.

14 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources1

Leaning Left0Leaning Right0Center0Last Updated13 days agoBias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

lifesciencesbc.ca broke the news in 14 days ago on Thursday, July 3, 2025.

Sources are mostly out of (0)

Quebec Implements Public Reimbursement of Pluvicto® – A Defining Milestone for Radioligand Therapy in Canada - Life Sciences British Columbia

1 Articles

1 Articles

Quebec Implements Public Reimbursement of Pluvicto® – A Defining Milestone for Radioligand Therapy in Canada - Life Sciences British Columbia

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics